These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11248169)

  • 1. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer.
    Marrelli D; Pinto E; De Stefano A; Farnetani M; Garosi L; Roviello F
    Am J Surg; 2001 Jan; 181(1):16-9. PubMed ID: 11248169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative positivity of serum tumor markers is a strong predictor of hematogenous recurrence of gastric cancer.
    Marrelli D; Pinto E; De Stefano A; de Manzoni G; Farnetani M; Garosi L; Roviello F
    J Surg Oncol; 2001 Dec; 78(4):253-8. PubMed ID: 11745820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
    Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
    Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer.
    Safi F; Kuhns V; Beger HG
    Int J Biol Markers; 1995; 10(2):100-6. PubMed ID: 7561233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
    Pectasides D; Mylonakis A; Kostopoulou M; Papadopoulou M; Triantafillis D; Varthalitis J; Dimitriades M; Athanassiou A
    Am J Clin Oncol; 1997 Aug; 20(4):348-53. PubMed ID: 9256887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer.
    Tian SB; Yu JC; Kang WM; Ma ZQ; Ye X; Cao ZJ; Yan C
    Asian Pac J Cancer Prev; 2014; 15(15):6295-300. PubMed ID: 25124614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
    Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J
    Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection.
    Marrelli D; Roviello F; De Stefano A; Fotia G; Giliberto C; Garosi L; Pinto E
    J Am Coll Surg; 2004 Jan; 198(1):51-8. PubMed ID: 14698311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma.
    Qiu MZ; Lin JZ; Wang ZQ; Wang FH; Pan ZZ; Luo HY; Li YH; Zhou ZW; He YJ; Xu RH
    Int J Biol Markers; 2009; 24(4):258-64. PubMed ID: 20082274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of serum CA 19-9 may be more valuable than CEA in prediction of recurrence in patients with gastric cancer.
    Tas F; Faruk Aykan N; Aydiner A; Yasasever V; Topuz E
    Am J Clin Oncol; 2001 Apr; 24(2):148-9. PubMed ID: 11319289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma.
    Marrelli D; Roviello F; De Stefano A; Farnetani M; Garosi L; Messano A; Pinto E
    Oncology; 1999 Jul; 57(1):55-62. PubMed ID: 10394126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
    Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
    Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
    Kim JH; Jun KH; Jung H; Park IS; Chin HM
    Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer.
    Li Y; Yang Y; Lu M; Shen L
    Hepatogastroenterology; 2011; 58(112):2166-70. PubMed ID: 22024091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer.
    Mattar R; Alves de Andrade CR; DiFavero GM; Gama-Rodrigues JJ; Laudanna AA
    Rev Hosp Clin Fac Med Sao Paulo; 2002; 57(3):89-92. PubMed ID: 12118264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
    Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic values of anti-helicobacter pylori antibody combined with serum CA724, CA19-9, and CEA for young patients with early gastric cancer.
    Gong X; Zhang H
    J Clin Lab Anal; 2020 Jul; 34(7):e23268. PubMed ID: 32118318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of serum CA 72-4 and CA 19-9 levels in gastric cancer patients and correlation with recurrence.
    Joypaul B; Browning M; Newman E; Byrne D; Cuschieri A
    Am J Surg; 1995 Jun; 169(6):595-9. PubMed ID: 7771623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer.
    Barillari P; Bolognese A; Chirletti P; Cardi M; Sammartino P; Stipa V
    Dis Colon Rectum; 1992 May; 35(5):471-6. PubMed ID: 1568399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.